BHCM
STRO icon

Brevan Howard Capital Management’s Sutro Biopharma STRO Stock Holding History

Brevan Howard Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,791
Closed -$468K – 2564
2026
Q1 		$468K Buy
+18,791
New +$340K ﹤0.01% 1339

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Brevan Howard Capital Management's STRO Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 18,791 shares — an estimated $468K sold.

Brevan Howard Capital Management first reported a position in STRO in Q1 2026 and held it in 1 quarter. The position peaked at $468K in Q1 2026. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 18,791 Sutro Biopharma shares in Q2 2026, an estimated $468K.
  • Brevan Howard Capital Management first reported a position in Sutro Biopharma in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Sutro Biopharma position peaked at $468K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.